GeneDx Holdings Corp. Restructuring Charges
GeneDx Holdings Corp. (WGS) reported Restructuring Charges of $3.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-03
- GeneDx Holdings Corp. restructuring charges for the quarter ending 2026-06-30 was $3.29M, a 4413.70% increase year-over-year.
- GeneDx Holdings Corp. restructuring charges for the quarter ending 2025-06-30 was $73.00K.
- GeneDx Holdings Corp. restructuring charges for the quarter ending 2023-12-31 was $1.98M.
- GeneDx Holdings Corp. restructuring charges for the quarter ending 2023-09-30 was $3.77M, a 99.98% decline year-over-year.
- GeneDx Holdings Corp. restructuring charges for fiscal 2024 was $1.75M, a 73.18% decline from fiscal 2023.
- GeneDx Holdings Corp. restructuring charges for fiscal 2023 was $6.53M, a 74.69% decline from fiscal 2022.
- GeneDx Holdings Corp. restructuring charges for fiscal 2022 was $25.81M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month | Restructuring Charges 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $3.29M 10-Q · filed 2026-08-03 | $3.73M 10-Q · filed 2026-08-03 | |||
| 2025-06-30 | $73.00K 10-Q · filed 2026-08-03 | $631.00K 10-Q · filed 2026-08-03 | |||
| 2024-12-31 | $1.75M 10-K · filed 2025-02-20 | ||||
| 2023-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $5.75M derived: sum of 2 quarters · filed 2025-02-20 | $6.21M derived: sum of 3 quarters · filed 2025-02-20 | $6.53M 10-K · filed 2025-02-20 | |
| 2023-09-30 | $3.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $4.22M derived: sum of 2 quarters · filed 2023-11-03 | $4.55M 10-Q · filed 2023-11-03 | -$18.52B derived: sum of 4 quarters · filed 2024-02-23 | |
| 2023-06-30 | $451.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $777.00K 10-Q · filed 2023-08-08 | -$18.53B derived: sum of 3 quarters · filed 2024-02-23 | $17.03M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2023-03-31 | $326.00K 10-Q · filed 2023-05-09 | -$18.53B derived: sum of 2 quarters · filed 2024-02-23 | $16.57M derived: sum of 3 quarters · filed 2024-02-23 | $23.44M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-12-31 | -$18.53B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $16.25M derived: sum of 2 quarters · filed 2024-02-23 | $23.11M derived: sum of 3 quarters · filed 2024-02-23 | $25.81M 10-K · filed 2024-02-23 | $24.16M 10-K · filed 2023-03-16 |
| 2022-09-30 | $18.54B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $18.55B derived: sum of 2 quarters · filed 2022-11-14 | $18.55B 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $6.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $9.56M 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $2.70M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |